High-dose chemotherapy in germ cell tumors: an old story still young..
Journal of Cancer Immunology and Therapy is an academic journal and aims to publish most complete and reliable source of information on the discoveries and current developments in the mode of original articles, review articles, case reports, short communications, etc. in all areas of the field and making them freely available through online without any restrictions or any other subscriptions to researchers worldwide. The journal selects the articles to be published with a single bind, peer review system, following the practices of good scholarly journals. It supports the open access policy of making scientific research accessible to one and all.
We are sharing one of the most cited article from our journal. Article entitled “High-dose chemotherapy in germ cell tumors: an old story still young.” was well written by Dr. Giovanni Rosti.
Germ cell tumours represent a model of curable solid tumours. In stage 1 and 2 more than 90% the patients can achieve cure, while in advanced cases such a goal is achieved in 70-80%. For metastatic cases the standard treatment has been for more than three decades the combination of cisplatin, etoposide and bleomycin (PEB) for three or four courses depending on the prognostic category (good or intermediate/poor). Surgery on the residuum is a fundamental part of the whole program, especially in non seminoma and all efforts have to be undertaken to remove residual disease. But despite these good results, a not negligible minority of patients do relapse usually in the first one or two years. Cure can still be achieved with second line chemotherapy in 25-40% of the patients, depending on type of relapse
Click the link to view full article: https://www.alliedacademies.org/articles/highdose-chemotherapy-in-germ-cell-tumors-an-old-story-still-young-8665.html
Manuscripts related to the above relevant topics can be submitted to the Journal through online or as an attachment to the E-mail: email@example.com. High quality submissions are expected to maintain the standard of the journal
Journal of Cancer Immunology and Therapy